Gilead prepares for anticipated hep C drug approval with plant expansion

If the FDA takes the recommendation from a panel that voted 15-0 last week to approve hep C treatment sofosbuvir, maker Gilead ($GILD) will be ready. It's expanding the facility that will manufacture the drug--a Canadian plant in Edmonton, Alberta--with additions worth $47 million. That will cover 45,000 square feet of lab and research space, which will come along with 80 jobs, the company says. More

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.